Dr. Hamid Fazal

Obesity, Food Addiction & Emotional Eating

A Comprehensive Physician Lecture & Clinical Reference

Dr. Hamid Fazal, MBBS, MD (USA), PGD (Nutrition)

Physician specializing in the intersection of chronic medical disease and mental health, managing complex metabolic conditions, neurodevelopmental care, and community psychiatry services.

01

Introduction & Paradigm Shift

Obesity is now clinically recognized as a chronic, relapsing, multifactorial neurobehavioral disease. Modern clinical approaches have shifted away from oversimplified "eat less, move more" advice toward an integrated understanding of appetite biology, reward circuitry, emotional regulation, and chronic metabolic management.

Multifactorial Drivers

  • ✔ Dysregulation of appetite & satiety
  • ✔ Reward pathway abnormalities
  • ✔ Environmental & psychosocial influences
  • ✔ Genetic predisposition
  • ✔ Hormonal & metabolic dysfunction
  • ✔ Behavioral conditioning

Frequent Comorbidities

  • ⚠ Anxiety disorders & Chronic Stress
  • ⚠ Depression & Psychological Trauma
  • ⚠ Attention-Deficit/Hyperactivity Disorder (ADHD)
  • ⚠ Sleep disorders & Deprivation
  • ⚠ Binge Eating Disorder (BED)
02

Definitions & Pathophysiology

Diagnostic Classification (BMI Cutoffs)

Classification WHO Standard Cutoffs South Asian Specific Cutoffs
Overweight 25.0 – 29.9 kg/m² ≥ 23.0 kg/m²
Obesity ≥ 30.0 kg/m² ≥ 25.0 kg/m²
Severe Obesity ≥ 40.0 kg/m² ≥ 30.0 kg/m²

Neuroendocrine Regulation of Appetite

Energy homeostasis is controlled by complex reciprocal signals between the hypothalamus, gut peptides, adipose tissue, and limbic pathways.

Leptin Satiety

Secreted by adipose tissue

Ghrelin Hunger

Secreted by stomach mucosa

GLP-1 Satiety ++

Delays gastric emptying

Dopamine Reward

Drives hedonic seeking

Insulin: Core peripheral metabolic control & satiety integration.
Peptide YY: Postprandial distal gut satiety signal.
Cortisol: Adrenal stress hormone driving visceral storage and reward-seeking.
03

Neurobiology of Food Addiction

Food addiction shows strong neurobiological overlap with classic substance use disorders. Highly processed hyper-palatable configurations (sugar, salt, and fat matrices) hyper-stimulate mesolimbic dopamine circuits, downregulating baseline receptor availability over time.

🧠 Nucleus Accumbens Reward Processing Center
🧠 Ventral Tegmental Area (VTA) Dopamine Synthesis Origin
🧠 Prefrontal Cortex Top-Down Inhibitory Deficit

Yale Food Addiction Scale (YFAS) Core Signs

• Intense, hard-to-resist cravings
• Loss of volume or intake control
• Continuing despite visible harm
• Subjective withdrawal-like states
• Increased tolerance over time
• Secretive eating patterns & guilt
04

Emotional Eating vs. Physical Hunger

Emotional eating is the consumption of food in response to emotional cues rather than somatic hunger signals. It serves as an artificial, dopamine-driven mechanism to downregulate distressing emotional states.

Characteristics of Emotional Hunger
  • ✕ Sudden Onset: Hits aggressively out of nowhere.
  • ✕ Highly Specific: Limits choices to comfort or ultra-processed food.
  • ✕ Perceived Urgency: Demands immediate response.
  • ✕ Persistent: Continues past safe physical fullness.
  • ✕ Postprandial Guilt: Followed by shame or self-disappointment.
Characteristics of Physical Hunger
  • ✓ Gradual Onset: Builds slowly over hours with clear physical cues.
  • ✓ Flexible Choices: Broad variety of whole foods are appealing.
  • ✓ Patient: Can be safely delayed or planned around.
  • ✓ Self-Limiting: Resolves smoothly once satiated.
  • ✓ No Post-Meal Remorse: Viewed as standard, necessary fuel.
05

Binge Eating Disorder (BED) Diagnostic Criteria

DSM-5-TR Core Frequency Rule: Binge eating episodes must occur at least once a week for 3 months, with clear absence of compensatory behavior (no regular purging, laxative abuse, or excessive fasting).

Associated Signs (Must feature ≥3 of the following)

• Eating much faster than normal velocity
• Eating until feeling uncomfortably full
• Eating large portions without physical hunger
• Eating alone due to performance embarrassment
• Marked post-episode distress, guilt, or self-disgust

Multisystem Medical Complications

Cardiometabolic: Type 2 Diabetes, HTN, Dyslipidemia, premature CAD, and Stroke.
Endocrine/GI: PCOS, male hypogonadism, severe GERD, NAFLD/NASH.
Respiratory/MSK: Severe Obstructive Sleep Apnea (OSA), severe Osteoarthritis.
Psychiatric: Treatment-resistant MDD, social anxiety, profound low self-esteem.
06

Clinical Assessment & Tools

Psychotropic Weight-Promoting Culprits

Antipsychotics: Olanzapine, Clozapine

Mood Stabilizers: Valproate

Antidepressants: Mirtazapine, Paroxetine, Amitriptyline

Metabolic/Other: Systemic Glucocorticoids, Insulin, Sulfonylureas

Targeted Diagnostic Screening Panel

PHQ-9 & GAD-7: Depression & generalized anxiety tracking
YFAS & SCOFF: Food addiction & core eating disorders
Epworth Scale: Excessive daytime drowsiness / Obstructive Sleep Apnea
Essential Laboratory Baseline Assessment

HbA1c, fasting lipid profile, Liver Function Tests (LFTs), Thyroid Function Tests (TFTs), Serum 25-hydroxyvitamin D, Complete Blood Count (CBC), Serum Creatinine, total free testosterone (selected symptomatic males), and early morning serum cortisol if Cushingoid features are physically visible.

07

Comprehensive Management Principles

Nutritional & Satiety Deficits

Prescribe high-protein, fiber-dense, low ultra-processed whole foods (e.g., eggs, fish, skinless poultry, legumes, oats, yogurt) to structurally sustain peripheral satiety signaling paths.

Behavioral Coping Tools

Deploy the HALT strategy (Identify if Hungry, Angry, Lonely, or Tired) coupled with 15-minute urge-delay pacing and positive sensory substitution tasks.

Sleep & Activity Optimization

Maintain 7–9 nightly sleep hours to control leptin-ghrelin balance. Target 150 min/week moderate cardiovascular load combined with regular progressive resistance training.

Clinical Communication Pivot: Motivational Interviewing

❌ Avoid Bias-Driven Framing

"You need more willpower and self-control."

"You simply need to demonstrate better discipline."

✅ Utilize Neurobiology-Driven Framing

"Your brain chemistry and key gut hormones strongly shape appetite signals."

"Obesity is a chronic, biological medical disease process, not a moral failure."

08

Anti-Obesity Pharmacotherapy Matrix

Clinical Indications: Consider pharmacology if BMI is ≥30 kg/m² or ≥27 kg/m² presenting with clear weight-related metabolic comorbidities.

Drug Class / Agent Primary Mechanism Mean Weight Loss Clinical Pearls & Key Target Subtypes
Semaglutide< class="block text-[10px] font-normal text-slate-500">(Wegovy - Weekly SC) Selective GLP-1 receptor agonist; delays gastric emptying, upregulates homeostatic brain satiety. 15% + Titrate slowly to reduce GI upset. Contraindicated in personal/family history of Medullary Thyroid Carcinoma or MEN2.
Tirzepatide< class="block text-[10px] font-normal text-slate-500">(Zepbound - Weekly SC) Dual GIP & GLP-1 receptor co-agonist; synergetic central appetite regulation. 20% + Demonstrates superior absolute weight loss and metabolic outcomes compared to monotherapy options in current head-to-head clinical trials.
Naltrexone / Bupropion< class="block text-[10px] font-normal text-slate-500">(Contrave - Oral) Hypothalamic POMC firing modulator & central mesolimbic reward system controller. 8% – 10% Ideal for explicit food addiction, severe craving patterns, and emotional eating. Avoid in active seizure states or uncontrolled HTN.
Phentermine / Topiramate< class="block text-[10px] font-normal text-slate-500">(Qsymia - Oral) Sympathomimetic amine appetite suppressant combined with GABA-mediated neuro-impulsivity control. 10% – 14% Highly effective for night eating syndrome and high-impulsivity binge tendencies. Side effects include paresthesia or mild cognitive slowing.
Orlistat< class="block text-[10px] font-normal text-slate-500">(Xenical - Oral) Reversible gastrointestinal lipase inhibitor; blocks peripheral dietary fat absorption by ~30%. 5% – 7% Limited by prominent gastrointestinal side effects (steatorrhea, flatulence). Requires fat-soluble vitamin supplementation.
Metformin: Modest benefit. Indicated primarily for secondary weight management in insulin resistance, metabolic syndrome, and antipsychotic-induced weight gain.
SSRIs (Fluoxetine/Sertraline): Beneficial for targeting underlying clinical depression, severe anxiety, or compulsive food habits; watch for long-term weight changes.
Lisdexamfetamine: Central nervous system stimulant. The sole FDA-approved pharmacological option indicated explicitly for moderate-to-severe Binge Eating Disorder (BED).
09

Bariatric Intervention & Pearls

Surgical Indications: BMI ≥40 kg/m², or BMI ≥35 kg/m² presentation with lifestyle-limiting clinical comorbidities. Lower thresholds are selectively indicated in vulnerable South Asian populations displaying high central visceral fat patterns.

Sleeve Gastrectomy Most common worldwide; restricts total gastric volume via partial restriction of the greater curvature.
Roux-en-Y Gastric Bypass Gold-standard metabolic option; combines clear volume restriction with malabsorptive tracking to shift gut hormones.
Psychological Clearance Pre-surgical psychiatric evaluation is essential to identify active severe BED, unmanaged depression, or substance use risk.
🚨 Clinical Red Flags & High-Risk Triggers

Immediately evaluate for rapid unprompted weight shifts, severe unmanaged binge-eating episodes, direct mechanical purging behaviors, new or worsening clinical depression, or active suicidal ideation.

Core Take-Home Lessons

📌 Obesity is a complex, neurobehavioral brain-body disease process requiring ongoing empathetic support.
📌 Food addiction patterns mirror classical chemical dependence neurobiology within dopamine-driven pathways.
📌 Shame-based, judgmental counseling models directly worsen patient compliance and psychological health outcomes.
📌 Modern GLP-1 and dual GIP co-agonist pharmacological options have fundamentally advanced long-term obesity treatment paradigms.